文献速递妇科

Demcizumab联合紫杉醇治疗铂耐药卵巢癌的Ib期试验

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
PubMed 文献 · Gynecol Oncol · 2020-02-07

SIERRA开放标签Ib期试验评估Demcizumab联合每周紫杉醇治疗铂耐药上皮性卵巢癌的安全性和初步疗效。最常见不良事件为腹泻、疲劳、外周水肿和恶心,客观缓解率21%,临床获益率42%。

要点

  • Demcizumab联合紫杉醇在铂耐药卵巢癌中毒性可控。
  • 未达到最大耐受剂量,未观察到剂量限制性毒性。
  • 客观缓解率21%,临床获益率42%,显示初步活性。

核心结论

  • Demcizumab联合紫杉醇毒性可控,在经多线治疗的铂耐药卵巢癌患者中显示活性。

主要发现

  • 未观察到剂量限制性毒性,未达到最大耐受剂量。
  • 最常见治疗出现的不良事件为腹泻(68%)、疲劳(58%)、外周水肿(53%)和恶心(53%)。
  • 观察到2级肺动脉高压2例和1级1例。
  • 客观缓解率为21%(95%CI:6-45%),临床获益率为42%(95%CI:20-66%)。

临床怎么用

  • Demcizumab联合紫杉醇可作为铂耐药卵巢癌的潜在治疗选择,需关注肺动脉高压等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the safety and preliminary efficacy of demcizumab (DLL4 targeted IgG2 humanized monoclonal antibody; potent inhibitor of the Notch pathway) in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer (EOC); and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD). METHODS: We conducted a 3 + 3 dose-escalation trial in patients with recurrent, platinum-resistant EOC with RECIST v. 1.1 measurable disease and ≤4 prior chemotherapy regimens. Two dosing cohorts (2.5 mg/kg and 5 mg/kg) were targeted; however, an intermediate dose level (3.5 mg/kg) was to be evaluated if the 5 mg/kg dose was not tolerable. Demcizumab was administered on days 1 and 15 and paclitaxel, weekly on days 1, 8, and 15 for each of three 28-day cycles: the 3-cycle doublet could be repeated once if safe. Thereafter, paclitaxel was administered until unacceptable toxicity or disease progression. RESULTS: Nineteen patients were enrolled. No dose-limiting toxicities (DLT) were observed; however, the intermediate dose level (3.5 mg/kg) was enrolled and expanded based on emerging safety data from other trials in the demcizumab program. The MTD was not reached. The most common treatment emergent adverse events (TEAE) were diarrhea (68%), fatigue (58%), peripheral edema (53%), and nausea (53%). Pulmonary hypertension, grade 2 (n = 2) and grade 1 (n = 1), was observed. Overall response rate (ORR) was 21% (95% CI: 6-45%); clinical benefit rate (CBR) was 42% (95% CI: 20-66%). CONCLUSIONS: Demcizumab in combination with paclitaxel has a manageable toxicity profile and showed activity in patients with heavily pretreated platinum-resistant ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Coleman RL, Handley KF, Burger R, et al. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. Gynecol Oncol. 2020. PMID: 32037195. doi:10.1016/j.ygyno.2020.01.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。